BackgroundThe mobilization of peripheral blood stem cells(PBSC) needs daily injection of granulocyte colony stimulating factor (G-CSF), which brings inconvenience to healthy donors. Can pegylated granulocyte colony-stimulating factor (Peg-G-CSF) solve this problem by single dose injection?MethodsThis multicenter, randomized controlled study was conducted from May 2018 to April 2019.
Eligible donors were randomly selected to received treatment with 12 mg Peg-G-CSF on day 1 or 10 µg/kg/d G-CSF consecutively from day 1. PBSC apheresis of the donors was conducted on day 5.
The primary endpoint was the percentage of donors who collected ≥4×106 CD34+cells/kg recipient weight after single apheresis.ResultsEighty (83.3%) of 96 donors in the Peg-G-SCF group and 76 (79.2%) of 96 donors in the G-CSF group collected ≥4×106 CD34+cells/kg recipient weight. The peak value of circulating CD34+ cell count occurred on day 5 in both groups.
The median yield of CD34+ cell collected in the Peg-G-CSF group was comparable to that in the G-CSF group by a single apheresis procedure.
Frontiers in Immunology published a clinical update in Infectious Disease on 24 Jun 2026.
The item focuses on Efficacy and safety of the single-dose pegylated G-CSF vs.
daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial.
Review the original article for the full source wording and details.